Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM

Bulletin Express
05/27

Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan Meeting Room, Wanda Vista Beijing.

Key agenda items are split into ordinary and special resolutions:

1. Ordinary resolutions • Approval of the Board Report, Supervisory Committee Report, audited consolidated financial statements and full Annual Report for the year ended 31 December 2025. • Endorsement of the 2025 profit distribution plan. • Review of the independent non-executive directors’ 2025 work report. • Confirmation of the directors’ remuneration (allowance) plan. • Re-appointment of the external auditor for the 2026 financial year.

2. Special resolutions • Granting a general mandate to the Board to repurchase H shares. • Granting a general mandate to the Board to issue H shares. • Abolishment of the Supervisory Committee and corresponding amendments to the Articles of Association.

Shareholders may appoint the chairman of the meeting or other designated proxies to vote on their behalf. The completed proxy form, together with any power of attorney, must be lodged with Computershare Hong Kong Investor Services Limited to be valid for the meeting.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10